CSF2 and neoplasm: Elizabeth Jaffee’s team was the first to identify MSLN as immunogenic protein, using GVAX (GM-CSF gene-transfected tumor cell vaccine), which originates from irradiated PDAC cells genetically engineered to secrete the granulocyte-macrophage colony-stimulating factor (GM-CSF).